The rise of Viagra and its influence on the medicinal landscape presents a complicated question for investors. While the first sales data were remarkable, the exclusivity has Pharma expired, leading to a flood of off-brand alternatives that are reducing earnings. Furthermore, the market is facing issues related to aging trends and shifting healthca